Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 39Neoplasm Metastasis 5Prostatic Neoplasms, Castration-Resistant 2Castration-resistant Prostate Cancer 2Thrombocytosis 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oligometastatic Prostate Carcinoma 1Oligo-metastatic Prostate Carcinoma 1Neoadjuvant Therapy 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Epoetin Alfa 10Darbepoetin alfa 8ferric carboxymaltose 7fludarabine 4Cyclophosphamide 4Busulfan 4Blood Transfusion 4fludarabine phosphate 3Filgrastim 3Erythrocyte Transfusion 3Cyclosporine 3Biopsy 3Antilymphocyte Serum 3thymoglobulin 2ruxolitinib 2iron isomaltoside 1000 2ferrous sulfate 2ferrous fumarate 2ferric gluconate 2Vitamin B 12 2Thiotepa 2Therapeutics 2Taxes 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Lenalidomide 2Folic Acid 2Ferric Oxide, Saccharated 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anemia × abiraterone × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡